Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

Ibrutinib has previously been shown to inhibit Bruton’s tyrosine kinase (BTK) and interleukin-2–inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell maligna...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood Adv
Главные авторы: Kumar, Anita, Vardhana, Santosha, Moskowitz, Alison J., Porcu, Pierluigi, Dogan, Ahmet, Dubovsky, Jason A., Matasar, Matthew J., Zhang, Zhigang, Younes, Anas, Horwitz, Steven M.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2018
Предметы:
Lymphoid Neoplasia
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915998/
https://ncbi.nlm.nih.gov/pubmed/29669753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017011916
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы